Head Of Japan's Controversial STAP Research Agrees To Retract Studies
This article was originally published in PharmAsia News
The head of Japan's controversial Riken institute research that published a pair of studies claiming success in stressing skin cells to turn them into induced pluripotent stem cells reportedly has agreed to withdraw both.
You may also be interested in...
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.
The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.